The RESOLVE study is a Phase 1b/2a clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI, an investigational drug, for the treatment of Eosinophilic Esophagitis (EoE).
A Phase 1, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of ANB033 in adult participants with eosinophilic esophagitis (EoE).